Charlaine van Steenis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Charlaine van Steenis has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Alaa Embaby
Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. 1
21 shared publications - Alwin D. R. Huitema
Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
21 shared publications - Bastiaan Nuijen
Netherlands Cancer Institute 5 Division of Pharmacy and Pharmacology Amsterdam, the Netherlands
21 shared publications - Christian U. Blank
Leiden University Medical Center, Leiden, The Netherlands
21 shared publications - Christopher G. Smith
Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK
21 shared publications - Cor Lieftink
Netherlands Cancer Institute, Amsterdam, Netherlands
21 shared publications
Latest Publications
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S7 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma
Supplementary Figure S7. Secondary mutations detected in ctDNA.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S7 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma
Supplementary Figure S7. Secondary mutations detected in ctDNA.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S4 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma
Supplementary Fig. S4. Vorinostat O-glucuronide plasma concentrations over time on days 1 and 14 of the first treatment cycle.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S4 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma
Supplementary Fig. S4. Vorinostat O-glucuronide plasma concentrations over time on days 1 and 14 of the first treatment cycle.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S3 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma
Supplementary Fig. S3. 4-AOA plasma concentrations over time on days 1 and 14 of the first treatment cycle.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S3 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma
Supplementary Fig. S3. 4-AOA plasma concentrations over time on days 1 and 14 of the first treatment cycle.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma
Supplementary Table S3. Results of RNA sequencing.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma
Supplementary Table S3. Results of RNA sequencing.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S2 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma
Supplementary Fig. S2. Vorinostat plasma concentrations over time on days 1 and 14 of the first treatment cycle.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S2 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma
Supplementary Fig. S2. Vorinostat plasma concentrations over time on days 1 and 14 of the first treatment cycle.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S3 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma
Supplementary Fig. S3. 4-AOA plasma concentrations over time on days 1 and 14 of the first treatment cycle.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S3 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma
Supplementary Fig. S3. 4-AOA plasma concentrations over time on days 1 and 14 of the first treatment cycle.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma
Supplementary Table S2. Tissue and ctDNA results.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma
Supplementary Table S2. Tissue and ctDNA results.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma
Supplementary Table S1. Representativeness of study participants.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma
Supplementary Table S1. Representativeness of study participants.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma
Supplementary Table S1. Representativeness of study participants.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma
Supplementary Table S1. Representativeness of study participants.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S2 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma
Supplementary Fig. S2. Vorinostat plasma concentrations over time on days 1 and 14 of the first treatment cycle.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S2 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma
Supplementary Fig. S2. Vorinostat plasma concentrations over time on days 1 and 14 of the first treatment cycle.